Ophthalmic drug compositions

A drug composition for use in a method of treatment of an ocular disease or condition, wherein the drug composition is for delivery to the suprachoroidal or supraciliary space by a device, wherein the composition comprises a semisolid material, wherein the semisolid material comprises a drug; flows under injection pressure; remains localised at the site of injection during and immediately after injection; and the semi-solid material undergoes dissolution after injection to migrate in the suprachoroidal space is provided. The semisolid material preferably comprises an excipient that undergoes dissolution, biodegradation or bioerosion. The excipient may be polyethylene oxide. The drug may be a steroid, a non-steroidal anti-inflammatory agent, a VEGF inhibitor, an anti-TNF alpha agent, an mTOR inhibitor, cell therapy, nucleic acid based therapeutic and/or a neuroprotectant. The drug may be dexamethasone. A device for delivery of a drug composition to the suprachoroidal space or supraciliary space is also described.